Who are pegylated interferon a-2a's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intron A, Peg-IFNα-2a, PegIFN alfa-2a, Peginterferon alfa 2, Peginterferon alfa 2 A, Pegylated interferon alpha 2.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pegylated-interferon-a-2a.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

pegylated interferon a-2a — Competitive Intelligence Brief

pegylated interferon a-2a (pegylated interferon a-2a) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Immunology, Virology.

marketed Interferon alpha Interferon alpha receptor (IFNAR) Immunology, Virology Small molecule Live · refreshed every 30 min

Target snapshot

pegylated interferon a-2a (pegylated interferon a-2a) — Foundation for Liver Research. Pegylated interferon alpha-2a activates innate immune responses by binding to interferon alpha receptors, enhancing antiviral and antiproliferative activity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
pegylated interferon a-2a TARGET	pegylated interferon a-2a	Foundation for Liver Research	marketed	Interferon alpha	Interferon alpha receptor (IFNAR)
Intron A	INTERFERON ALFA-2B	Merck & Co.	marketed	Interferon alpha		1986-01-01
Peg-IFNα-2a	Peg-IFNα-2a	Beijing 302 Hospital	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa 2	Peginterferon alfa 2	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peginterferon alfa 2 A	Peginterferon alfa 2 A	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Pegylated interferon alpha 2	Pegylated interferon alpha 2	Ain Shams University	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

Dr. Conrado Fernandez · 2 drugs in this class
Ain Shams University · 1 drug in this class
Beijing 302 Hospital · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Kexing Biopharm Co., Ltd. · 1 drug in this class
Merck & Co. · 1 drug in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). pegylated interferon a-2a — Competitive Intelligence Brief. https://druglandscape.com/ci/pegylated-interferon-a-2a. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab